Free Daily Podcast Summary
The Readout Loud: Daily Summaries Delivered
by STAT
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 6 days ago36 min
405: An obesity drug deep-dive, and peptides move mainstream
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.[2:37 PM]Undark’s Sara Talpos joins the podcast to discuss her reporting on the peptide BPC-157, and how its jumped from a Croatian lab to bodybuilding forums on Reddit to the FDA. (STAT co-published Talpos articles; the second piece was was supported by the Pulitzer Center). We also discuss the latest news in the life sciences, including obesity data from the American Diabetes Association meeting and a record-breaking IPO.
- 1 weeks ago37 min
404: What RevMed's pancreatic cancer drug meant for one patient
Why did oncologists give a standing ovation to a data presentation on Revolution Medicines' pancreatic cancer drug, daraxonrasib? Why did biotech stocks perform so badly this week? And are concrete beaches better than normal beaches? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. We bring on Leanna Stokes, who was diagnosed with metastatic pancreatic cancer in 2023. She discusses how participating in RevMed's trial for daraxonrasib has affected her disease and life, and what the drug means for patients and the field. We also chat about other data presented during last week's meeting of the American Society of Clinical Oncology, the market reaction to Abivax's ulcerative colitis data, and the upcoming meeting of the American Diabetes Association.
- 2 weeks ago47 min
403: Biotech exec Jeremy Levin on the industry's strategic turning point
On this week’s episode of “The Readout LOUD,” we chat with longtime biotech executive Jeremy Levin about his new book, “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust.” That sounds alarmist, and it is in some respects, but as Levin explains, the book is also a roadmap to a brighter future for the biotech industry.
- 3 weeks ago44 min
402: Guarding biotech from China and big bets in longevity
On this week’s episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from health care and science rubbed shoulders. They share some of the juicy conversations and insights, including BridgeBio CEO Neil Kumar's comments that the company is publishing “not the right structures” in their research publications. Listeners also will hear Allison's interview with Joe Betts-LaCroix, CEO of the Sam Altman-backed longevity company Retro Biosciences. Retro is preparing for its first clinical data readout and examining just how much impact AI can have in drug development. The hosts also discuss colleague Damian Garde's article on how China is tearing biotech apart and one self-appointed spokesperson’s strategy.
- May 14, 202640 min
401: Makary’s departure and Cassidy’s tenuous Senate seat
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he is leaving, which of his policies will stick, and what we know about his acting replacement, Kyle Diamantas. Washington correspondent Chelsea Cirruzzo also joins us to discuss a closely tracked Republican Senate primary election this weekend. Bill Cassidy, chair of the Senate health committee, is up against two upstart rivals, including a Trump-backed candidate. The outcome of the primary could have far reaching implications for Trump’s health care agenda.
- May 7, 202633 min
400: Seaport's IPO adventure, obesity pill battles, and Makary's troubles
On this week’s episode of "The Readout LOUD," we chat with Seaport Therapeutics CEO Daphne Zohar, fresh off the biotech’s successful IPO. Plus, Elaine, Allison, and Adam chat about this week’s notable news, including the obesity pill battle between Eli Lilly and Novo Nordisk, a Phase 3 study win for Cytokinetics, and FDA Commissioner Marty Makary’s White House troubles. Oh, by the way, this is the 400th episode of your favorite biotech podcast.
- Apr 30, 202641 min
399: Hair-raising trial results, and Servier’s M&A wishlist
Why are investors excited about hair loss drugs? Will artificial intelligence make clinical trials run more smoothly? And how does a nonprofit pharma company compete in the M&A arena? We get into all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Veradermics CEO Reid Waldman joined us to discuss his company’s data, and why hair loss is such a trendy topic in biotech. Then, Servier Pharmaceuticals CEO David Lee joined us to discuss the company’s acquisition of Day One Biopharmaceuticals.
- Apr 23, 202637 min
398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
How did a biotech company that almost ran out of money three times get acquired for over $3 billion? Will the M&A streak continue? And why are drugmakers working with a telehealth company called Prescribery? We discuss all that and more on this week's episode of "The Readout LOUD," STAT's weekly biotech podcast. Venture capitalist Bryan Roberts joins us to discuss his firm’s investment in Kelonia Therapeutics, the CAR-T biotech that Eli Lilly just said it would buy for $3.25 billion. We also bring on our colleague Katie Palmer to talk through her story about pharma companies using bargain-basement telehealth providers to drive drug prescriptions and sales.
Get The Readout Loud summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Stock Movers
Daily analysis of top-performing and struggling stocks across global markets, covering major sectors and breaking investment news.
Plenary Session
Discusses medicine, oncology, and health policy with expert guests and critical analysis.
Drug Story
Each episode explores the unexpected stories behind prescription drugs and the business of treating illness.
Pivot
Sharp, unfiltered analysis of tech, business, and politics with bold predictions and lively debate.
Relentless Health Value
Healthcare professionals work to reduce waste and fix broken incentives in the U.S. medical system through transparency and practical solutions.
The Best One Yet
Daily business news explained through sharp analysis and witty commentary, delivered in concise 20-minute episodes.
Biostatistics Podcast
A podcast exploring various topics in biostatistics.
Peptide of The Week
Explores peptides, performance optimization, and health through science-backed discussions on diet, training, recovery, and mindset.
Unbiased Science
Two scientists analyze health topics using objective, evidence-based approaches to inform everyday decisions.
Becker’s Healthcare Podcast
Daily 15-minute episodes covering U.S. healthcare news, analysis, and insights from industry leaders.
The Pulse
Explores surprising stories in health and science, from operating rooms and labs to breakthrough innovations.
Wellness, Actually with Emily Oster & Perry Wilson, MD
Two experts analyze health news, debunk wellness myths, and answer listener questions using data and medical evidence.
About The Readout Loud
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The Readout Loud in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The Readout Loud daily summary?
It's a free AI-powered email that summarizes new episodes of The Readout Loud as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The Readout Loud podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The Readout Loud product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by STAT.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does The Readout Loud release new episodes?
The Readout Loud publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does The Readout Loud cover?
The Readout Loud covers topics including Business. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The Readout Loud summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.